ABSTRACT Metformin hydrochloride is widely used as an oral anti hypoglycemic agent. But it is difficult to formulate by direct compression method because of its poor compaction properties and its crystalline nature. The present study target for a better combination of binders that produces metformin tablets with unique results. The granulation is done using binder combination of gelatin, PVP K 30, HPMC, Cross Povidone, starch and Kyron-T 314. The wet granulation method is selected for the formulation of metformin tablets and the formulated tablets were evaluated for their hardness, friability, disintegration, content uniformity and dissolution profiles with USP type II apparatus at 100 rpm in pH 6.8 phosphate buffer solution. Th
In this research study an attempt was made to formulate sustained release matrix tablets of Metformi...
The objective of the present study was to study the effect of hydrophilic polymers on sustained rele...
Metformin hydrochloride (MH), an important drug in the treatment of type II diabetes mellitus, requi...
Metformin hydrochloride (MH) is an oral hypoglycemic agent and a high-dose drug that has poor flow a...
INTRODUCTION:Oral drug delivery is the fastest and more preferred route for the drug administration...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The present study was aimed at developing, evaluating and optimization of the oral hypoglycaemic dru...
The aim of this study was to evaluate binders to improve the flowability of granulates and compactib...
AbstractThe aim of this study was to evaluate binders to improve the flowability of granulates and c...
Floating tablet is one of the most suitable dosage forms that used for delivering long term drug rel...
AbstractThe present work explores the application of melt granulation technology to develop a high d...
Objective: The objective of the present study was to formulate, study the in-vitro release kinetics ...
 Objective: The aim of this investigation was to develop and optimize metformin hydrochloride matri...
The present study formulation and evaluation of sustained release metformin hydrochloride matrix ta...
Objective: The purpose of this study was to develop and evaluate bi-layer tablets for the immed...
In this research study an attempt was made to formulate sustained release matrix tablets of Metformi...
The objective of the present study was to study the effect of hydrophilic polymers on sustained rele...
Metformin hydrochloride (MH), an important drug in the treatment of type II diabetes mellitus, requi...
Metformin hydrochloride (MH) is an oral hypoglycemic agent and a high-dose drug that has poor flow a...
INTRODUCTION:Oral drug delivery is the fastest and more preferred route for the drug administration...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The present study was aimed at developing, evaluating and optimization of the oral hypoglycaemic dru...
The aim of this study was to evaluate binders to improve the flowability of granulates and compactib...
AbstractThe aim of this study was to evaluate binders to improve the flowability of granulates and c...
Floating tablet is one of the most suitable dosage forms that used for delivering long term drug rel...
AbstractThe present work explores the application of melt granulation technology to develop a high d...
Objective: The objective of the present study was to formulate, study the in-vitro release kinetics ...
 Objective: The aim of this investigation was to develop and optimize metformin hydrochloride matri...
The present study formulation and evaluation of sustained release metformin hydrochloride matrix ta...
Objective: The purpose of this study was to develop and evaluate bi-layer tablets for the immed...
In this research study an attempt was made to formulate sustained release matrix tablets of Metformi...
The objective of the present study was to study the effect of hydrophilic polymers on sustained rele...
Metformin hydrochloride (MH), an important drug in the treatment of type II diabetes mellitus, requi...